ArticleJournal of controlled release : official journal of the Controlled Release Society2020
Peptides as surface coatings of nanoparticles that penetrate human cystic fibrosis sputum and uniformly distribute in vivo following pulmonary delivery.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Design and Production of Respirable Effervescent Microparticles to Enhance Drug Penetration Through Lung Mucus.Pharmaceutics · 2026Article
- Unraveling Oral Fate of Poly(Lipoic Acid)s: Mechanistic Insights and Delivery Horizons.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Inhalable gene and RNA therapy for cystic fibrosis: perspectives and progress in clinical development.Nanomedicine (London, England) · 2026Review
- A Comprehensive In-Silico Pipeline for the Discovery of Non-toxic, Stable Antimicrobial Peptides From Databases for Targeting Multi-Drug ResistantBioinformatics and biology insights · 2026Article
- Structure-guided design of nucleosome-inspired nanoparticles for overcoming pulmonary barriers in fibrotic lung gene therapy.Science advances · 2025Article
- Oral targeting tilianin nanoplatform mitigates atherosclerosis through promoting macrophage phagocytosis and anti-inflammation.Materials today. Bio · 2025Article
- Tailored Levofloxacin Incorporated Extracellular Matrix Nanoparticles for Pulmonary Infections.International journal of molecular sciences · 2025Article
- Nanoparticle-Based Pulmonary Immune Engineering.Annual review of chemical and biomolecular engineering · 2025Review
- Recent strategies for enhanced delivery of mRNA to the lungs.Nanomedicine (London, England) · 2025Review
- The mucosal protein corona in local nanoparticle drug delivery.Cell biomaterials · 2025Article
- Low Molecular Weight Alginate Oligosaccharides as Alternatives to PEG for Enhancement of the Diffusion of Cationic Nanoparticles Through Cystic Fibrosis Mucus.Advanced healthcare materials · 2025Article
- Breath and Beyond: Advances in Nanomedicine for Oral and Intranasal Aerosol Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia.Molecular therapy. Nucleic acids · 2024Article
- LysSYL-Loaded pH-Switchable Self-Assembling Peptide Hydrogels Promote Methicillin-Resistant Staphylococcus Aureus Elimination and Wound Healing.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Synthetic mucus barrier arrays as a nanoparticle formulation screening platform.RSC pharmaceutics · 2024Article
- Recent Progress in Nucleic Acid Pulmonary Delivery toward Overcoming Physiological Barriers and Improving Transfection Efficiency.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Thiophene-based lipids for mRNA delivery to pulmonary and retinal tissues.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Phage Display Identified Novel Leydig Cell Homing Peptides for Testicular Targeting.ACS pharmacology & translational science · 2024Article
- Synthetic mucus barrier arrays as a nanoparticle formulation screening platform.bioRxiv : the preprint server for biology · 2023Article
- Nanoparticle-Mediated Strategies for Enhanced Drug Penetration and Retention in the Airway Mucosa.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Therapeutic delivery of drug and gene delivery systems have to traverse multiple biological barriers to achieve efficacy. Mucosal administration, such as pulmonary delivery in cystic fibrosis (CF) disease, remains a significant challenge due to concentrated viscoelastic mucus, which prevents drugs and particles from penetrating the mucus barrier. To address this problem, we used combinatorial peptide-presenting phage libraries and next-generation sequencing (NGS) to identify hydrophilic, net-neutral charged peptide coatings that enable penetration through human CF mucus ex vivo with ~600-fold better penetration than control, improve uptake into lung epithelial cells compared to uncoated or PEGylated-nanoparticles, and exhibit enhanced uniform distribution and retention in the mouse lung airways. These peptide coatings address multiple delivery barriers and effectively serve as excellent alternatives to standard PEG surface chemistries to achieve mucus penetration and address some of the challenges encountered using these chemistries. This biomolecule-based strategy can address multiple delivery barriers and hold promise to advance efficacy of therapeutics for diseases like CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.